コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 onment cells and induces osteoclast-mediated osteolysis.
2 alter its microenvironmental niche favoring osteolysis.
3 among the nuclei of giant cells at sites of osteolysis.
4 re DCs were readily recruited to the site of osteolysis.
5 ppaB ligand (RANKL) to promote breast cancer osteolysis.
6 h which MMP-7 mediates mammary tumor-induced osteolysis.
7 e represents a potential avenue to interrupt osteolysis.
8 es of Runx2 in facilitating tumor growth and osteolysis.
9 g SNPs were not individually associated with osteolysis.
10 KL and were protected from arthritis-induced osteolysis.
11 of cathepsin G reduces mammary tumor-induced osteolysis.
12 tor beta (TGFbeta)-mediated tumor growth and osteolysis.
13 gene for IL-6 is positively associated with osteolysis.
14 osteolytic bone metastasis and inflammatory osteolysis.
15 -expressing tumors caused significantly more osteolysis.
16 r Runx2 subnuclear targeting is required for osteolysis.
17 xpression was also associated with decreased osteolysis.
18 s is a fundamental component of inflammatory osteolysis.
19 -1 plays a role in TNF-induced periarticular osteolysis.
20 n will have activity in inflammation-induced osteolysis.
21 pha is the dominant cytokine in inflammatory osteolysis.
22 view will update the state of periprosthetic osteolysis.
23 cell growth in bone marrow and accompanying osteolysis.
24 x is a viable strategy to avert inflammatory osteolysis.
25 t consist of a mixture of osteosclerosis and osteolysis.
26 joint swelling, osteoclast recruitment, and osteolysis.
27 -1alpha) in multiple myeloma (MM)-associated osteolysis.
28 ebris-induced bone loss in a murine model of osteolysis.
29 HMWPE) particles to provoke inflammation and osteolysis.
30 ne production, 2) osteoclastogenesis, and 3) osteolysis.
31 loma and skeletal metastases associated with osteolysis.
32 convenient target in arresting inflammatory osteolysis.
33 or its p55 receptor may arrest wear particle osteolysis.
34 eriodontitis, is often complicated by severe osteolysis.
35 ients with advanced disease and causes local osteolysis.
36 protection against LPS-induced inflammatory osteolysis.
37 yeloma (MM) but does not enable detection of osteolysis.
38 d Th1 cells and accelerated tumor growth and osteolysis.
39 ent of selective treatments for inflammatory osteolysis.
40 oach for the treatment of myeloma associated osteolysis.
41 cs accelerated intraosseous tumor growth and osteolysis.
42 needed to optimize treatment of inflammatory osteolysis.
43 isease presenting with osteoporosis and acro-osteolysis.
44 tion of wear debris-induced inflammation and osteolysis.
45 s and root resorption), osteopenia, and acro-osteolysis.
46 of postmenopausal osteoporosis and cancerous osteolysis.
47 , underdeveloped cheekbones, and marked acro-osteolysis.
48 ic toxicity to prevent wear particle-induced osteolysis.
49 twork in inflammatory osteoclastogenesis and osteolysis.
50 an important role in cancer invasion of bone/osteolysis.
51 cell carcinoma (OSCC) tumor progression and osteolysis.
52 utic target to prevent OSCC invasion of bone/osteolysis.
53 and consistent with induction of osteocytic osteolysis.
54 e commonly associated with hypercalcemia and osteolysis.
55 enesis, extracellular matrix proteolysis and osteolysis.
56 wth through immunosuppression and aggressive osteolysis.
57 eoclast differentiation and overall promotes osteolysis.
58 ovel target in treating breast tumor-induced osteolysis.
59 facial developmental abnormalities, and acro-osteolysis.
60 and consequently are inefficient in causing osteolysis.
61 s ago in two sisters with a severe crippling osteolysis.
62 clopidogrel, were protected from pathologic osteolysis.
63 educed tumor growth in bone despite enhanced osteolysis.
64 uction via activation of osteoclast-mediated osteolysis.
65 diponectin promotes myeloma tumor growth and osteolysis.
66 is (OA) and particle-mediated periprosthetic osteolysis.
67 i2 overexpression in tumor cells can promote osteolysis.
68 cesses critically involved in periprosthetic osteolysis: 1) wear debris-induced proinflammatory cytok
69 -like lesions were also associated with acro-osteolysis (10 [37.0%] vs 62 [12.9%]; P < .01), digital
70 have occurred in vivo as part of osteocytic osteolysis, a mechanism of mineral homeostasis, supporti
71 reduced incidence of in vivo tumor-mediated osteolysis after intratibial injection of tumor cells in
72 e been found in patients with periprosthetic osteolysis after second generation metal-on-metal prosth
73 llele is associated with a decreased risk of osteolysis after THA and with increased IL-1 receptor an
76 moted bone metastasis, leading to manifested osteolysis and accelerated death in mice, while DLC1 ove
77 s a key player in Ewing sarcoma invasion and osteolysis and also in the differential phenotype of Ewi
80 G may be an effective therapy for preventing osteolysis and decreasing skeletal tumor burden in patie
83 ctional sequelae of Btk activation mediating osteolysis and growth of MM cells, supporting evaluation
84 otes wound healing and inhibits inflammatory osteolysis and hypothesized that A2AR might be a novel t
85 Effects on bone were associated with reduced osteolysis and increased periosteal new bone formation.
86 roadens the understanding of myeloma-induced osteolysis and indicates a potential strategy for disrup
87 of rare skeletal disorders characterized by osteolysis and joint destruction, which can mimic severe
88 ions related to polyethylene wear (including osteolysis and loosening); 0.652-0.783 sensitivity and 0
89 s establish that ZOL can reduce OSCC-induced osteolysis and may be valuable as an adjuvant therapy in
90 A enzymatic activity effectively interrupted osteolysis and metastatic progression in preclinical mod
91 pression of genes associated with osteocytic osteolysis and osteoclastic bone resorption compared to
92 ice were partially protected from osteocytic osteolysis and osteoclastic bone resorption when allowed
93 pression of genes responsible for osteocytic osteolysis and osteoclastic resorption than the WT femal
97 targeted agents to inhibit tumour-associated osteolysis and prevent skeletal morbidity as well as use
98 at both strains caused comparable degrees of osteolysis and reactive new bone formation in the acute
99 ronic acid (ZOL) would inhibit tumor-induced osteolysis and reduce tumor growth and invasion in a mur
100 n lung cancer in nude mice induces extensive osteolysis and severe hypercalcemia, daily administratio
101 d key role for heparanase in promoting tumor osteolysis and show that RANKL is central to the mechani
102 s an important role in mammary tumor-induced osteolysis and suggest that cathepsin G is a potentially
103 e TB interface is important in tumor-induced osteolysis and suggest that MMP13 is a potential therape
104 to the development of myeloma and associated osteolysis and that disruption of these interactions usi
105 ice respond more strongly to locally induced osteolysis and that Fbn1(mgR/mgR) osteoblasts stimulate
106 ated for prevention of wear particle-induced osteolysis and the loss of fixation in a murine prosthes
107 oosening, 35 instability, 10 stiffness, five osteolysis, and 17 other) and 110 from subjects with PJI
108 evidence for microgravity-induced osteocytic osteolysis, and CDKN1a/p21-mediated osteogenic cell cycl
109 ion; however, we hypothesize that osteocytic osteolysis, and cell cycle arrest during osteogenesis ma
112 , through which malignant plasma cells drive osteolysis, and explain how bisphosphonates can be used
113 bone colonization, diminished tumor-mediated osteolysis, and lessened bone density decrement in mice
115 aniofacial developmental abnormalities, acro-osteolysis, and osteoporosis and is associated with gain
117 d soft tissue inflammation, periostitis with osteolysis, and periosteal new bone formation progressin
118 to inhibit tumor-induced osteoclastogenesis, osteolysis, and skeletal tumor burden in two animal mode
119 l-induced osteoclastogenesis and exacerbated osteolysis, and these effects were attenuated in culture
121 r growth in soft tissue, metastasis to bone, osteolysis, and tumor growth in bone, with maximum effec
122 implicated in MM-related processes including osteolysis, angiogenesis, immune suppression, and drug r
123 econdary findings, including -periprosthetic osteolysis, angulation of the implant, fracture, or abno
124 onstrated that the novel autosomal recessive osteolysis/arthritis syndrome, multicentric osteolysis w
126 x) was able to prevent wear particle-induced osteolysis, as assessed by micro-CT and histological ana
128 NKL/RANK/OPG signaling) is implicated in the osteolysis associated with diabetic Charcot neuroarthrop
131 human data suggest that BPs not only reduce osteolysis associated with metastatic breast cancer, but
134 mice through cardiac ventricles caused bone osteolysis at a frequency approximately 85% higher than
137 ive), JWH015 and AM1241 (CB(2)-selective) in osteolysis-bearing females (MD 8.18, (95%)CI 6.14, 10.21
139 s of pooled studies showed that treatment of osteolysis-bearing males with the endocannabinoids AEA a
140 s novel role for heparanase as a promoter of osteolysis before tumor metastasis suggests that therapi
141 lid components, foci of wall susceptibility, osteolysis, bone marrow edema, abductor muscle or tendon
142 lecular weight polyethylene particle-induced osteolysis, bone reconstruction, and periosteal inflamma
144 imately 50% lower bone mass due to increased osteolysis, but there is no systemic inflammation and no
145 butes to the cancer cell-mediated program of osteolysis by inducing matrix degradation through MMP2.
146 at ankle loading suppresses tumor growth and osteolysis by inhibiting bone resorption and enhancing b
147 r-bone interface has the potential to reduce osteolysis by inhibiting the recruitment, differentiatio
149 and bone marrow, and may promote RBM-induced osteolysis by stimulating the recruitment and differenti
151 ively, these data indicate that inflammatory osteolysis can be abrogated by treatment with a molecule
152 is a major factor involved in tumor-induced osteolysis caused by breast cancers that have metastasiz
153 88, primarily in osteocytes, protect against osteolysis caused by calvarial injections of bacterial P
157 early as post-implantation day (PID) 3, but osteolysis does not begin until PID 6, correlating with
159 myeloma cell line 5TGM1, which causes severe osteolysis, expresses alpha(4)beta(1)-integrin and tight
160 Another bone disorder, familial expansile osteolysis (FEO), although extremely rare, also is chara
162 he uncommon IL6 haplotype -174G/-572G/-597A (osteolysis group frequency 2.4%, control group frequency
166 ances in our understanding of periprosthetic osteolysis, imaging technology to quantify osteolysis, a
169 ort that simvastatin acts as an inhibitor of osteolysis in a mouse model of breast cancer skeletal me
170 ssociated with TARP implantation, decreasing osteolysis in adjacent vertebrae and preserving disc cel
172 tate cancer cells increases tumor growth and osteolysis in an intratibial mouse model of bone metasta
173 pressed osteoclastogenesis and tumor-induced osteolysis in an orthotopic breast cancer bone metastasi
174 at osteocytes directly regulate inflammatory osteolysis in bone infection, suggesting that MYD88 and
176 as phenotypes of osteopetrosis in tibiae and osteolysis in calvariae as a result of cathepsin K mutat
178 Cytokine induction is thought to stimulate osteolysis in conditions such as periodontal disease and
191 tle is known of the pathophysiology of local osteolysis in the skeleton or its prevention and treatme
193 F-alpha, anti-c-Fms also completely arrested osteolysis in TNF-injected mice with nominal effect on m
196 multiple prostate cancer cells and promotes osteolysis in vivo in an immunodeficient mouse model of
197 these data suggest that PTHrP expression and osteolysis in vivo in human breast cancer cells is drive
198 vIL-10 administration on wear debris-induced osteolysis in vivo were analyzed using the mouse calvari
199 he effects of Gli2 on breast cancer-mediated osteolysis in vivo, athymic nude mice were inoculated wi
202 ortance to disorders, such as periprosthetic osteolysis, in which granulomatous inflammation is initi
203 n bone tissue as well as genes important for osteolysis, including HIF1alpha, JAG1, IL6, and VEGF.
204 ray nanoCT studies revealed signs of lacunar osteolysis, including increases in cross-sectional area
205 be a pathway by which bacteria could enhance osteolysis independently of osteoblasts and suggest that
206 o groups was found regarding the presence of osteolysis (infection group, 23 of 40; control group, 60
207 ologic bone loss in TNF-induced inflammatory osteolysis, inflammatory arthritis and post-ovariectomy
213 astasis, which is characterized by extensive osteolysis leading to severe bone pain and pathologic fr
214 discoveries advancing the treatment of focal osteolysis, leading to development of therapeutic agents
215 TNF is essential to development of particle osteolysis, mice failing to express both the p55 and p75
216 he functional role of MMP13 in tumor-induced osteolysis, mice with Cl66 mammary tumors were treated w
219 ntric carpal-tarsal osteolysis; multicentric osteolysis, nodulosis, and arthropathy; and Winchester s
222 MM cell growth (P < .03) and MM cell-induced osteolysis of implanted human bone chips in SCID mice.
223 ration in the absence of osteopenia or focal osteolysis on standard metastatic bone surveys (MBSs).
224 ed macrophages from multicentric carpotarsal osteolysis (Online Mendelian Inheritance in Man #166300)
226 odds ratio [OR], 20.1; 95% CI: 5.7, 70.9) or osteolysis (OR, 3.1; 95% CI: 1.8, 5.3), absence of any n
227 e chemokine's effects are direct, to enhance osteolysis, or indirect and mediated through a reduction
228 erials, causing inflammation, periprosthetic osteolysis, osteomyelitis, and bone damage, resulting in
229 e development of bone loss diseases, such as osteolysis, osteoporosis, and rheumatoid arthritis.
230 ol group frequency 0.8%) was associated with osteolysis (P=0.02, calculated using Haploview software)
232 ce type (normal, fibrous membrane, fluid, or osteolysis), percent integration (<33%, 33%-66%, or >66%
240 NOTCH2, is clinically characterized by acro-osteolysis, severe osteoporosis, short stature, neurolog
241 esis, particularly in states of inflammatory osteolysis such as that attending rheumatoid arthritis.
242 nce of inflammatory diseases associated with osteolysis, such as rheumatoid arthritis (RA), often lea
243 Rep-expressing cells exhibited a decrease in osteolysis, suggesting that Gli2 inhibition may block TG
245 he greatest abnormality in the carpal-tarsal osteolysis syndromes are regions of subarticular ossific
247 In contrast to overt metastasis causing osteolysis, TCM treatment induced new bone formation tha
248 ted with halofuginone had significantly less osteolysis than mice receiving placebo assessed by radio
249 pivotal to the pathogenesis of inflammatory osteolysis, the means by which it recruits osteoclasts a
250 w and development of associated osteoclastic osteolysis through cell-cell interactions have been indi
251 romotes bone tumor burden and tumor-mediated osteolysis through combined control of tumor proliferati
252 o stimulated systemic osteoclastogenesis and osteolysis, thus mimicking the systemic osteoporosis oft
254 ZOL-mediated inhibition of tumor-induced osteolysis was characterized by reduced numbers of tartr
255 ability of SH2(N+C) to prevent inflammatory osteolysis was examined in vivo following RANKL or LPS i
256 ent, arguing that ZOL-mediated inhibition of osteolysis was independent of effects on osteoclast acti
257 Heterotopic ossification or postoperative osteolysis was not significantly associated with either
259 an animal model of calvaria-induced aseptic osteolysis was used to analyze possible bone resorption
260 dentify a soluble mediator of periprosthetic osteolysis we first showed that implant particles induce
261 est the hypothesis that TNF mediates implant osteolysis, we established an in vivo murine model of th
263 ontributes to tumor growth and tumor-induced osteolysis whereas osteoclast-derived MMP-9 had no effec
264 us tumors than Neo control cells and induced osteolysis, whereas DU145 MT1-MMP-silenced transfectants
265 osteolysis/arthritis syndrome, multicentric osteolysis with arthritis (MOA) (MIM #605156), was cause
266 an autosomal recessive form of multicentric osteolysis with carpal and tarsal resorption, crippling